Sanofi Diabetes
Pay No More Than $25 on up to 12 Lantus® SoloSTAR® pen prescriptions and get ongoing support. Certain restrictions apply. Learn more >>
For U.S. Residents Only
A A A

Change font size  A A A Email Print Prescribing Information Site Map

Close

Lantus® is a once-daily, long-acting insulin that provides 24-hour basal
coverage with no pronounced peak.1

How Lantus® Works Lantus® Efficacy Lantus® Safety Lantus®
SoloSTAR® Pen
View video
  1. Lantus® Prescribing Information. October 2013.
Close

Dosing guidelines and titration for Lantus®

Dosing Titration
Interactive dosing calculator Titration options
Close

Education is an important part of prescribing insulin therapy to help manage
patients' concerns about insulin use.

Therapy Considerations Initiating Treatment Improving Self-Management
Stepwise Approach
Close

Provide educational support for your patients with type 2 diabetes.
Help them understand, know what to expect, and become active participants in their own care.

Day by Day Guide Explaining Diabetes to Patients Getting Patients Started Improving Patient
Self-Care Skills
Useful guides to reinforce your conversations with patients
Close

There are a variety of ways Sanofi can help your patients access their insulin therapy.

Formulary Tool Patient Assistance Savings Offer
Save on Lantus® SoloSTAR®

* Certain eligibility restrictions apply

Close

Tools, links, and educational materials to help you support patients move
toward their glycemic goals.

Professional Resources Patient Resources
Educational materials

Basal-Plus 1 Regimen

Proven A1C reduction with a Basal-Plus 1 regimen1 eases patients into mealtime therapy

ADA/EASD Consensus Statement

Prandial insulin can be added in a stepwise fashion, starting with 1 dose at the largest meal2

Progressive deterioration of ß-cell function

Adapted from Raccah 2008.3

In the OPAL study, the Apidra® Basal-Plus 1 regimen helped patients reach A1C goal1

  • Treatment equivalence of the 2 mealtime Apidra® regimens was demonstrated
  • Adding 1 dose of Apidra® a day achieved significant A1C reductions from baseline to endpoint-breakfast group, from 7.35% to 7.03%; main meal group, from 7.29% to 6.94% (P<0.0001)

A1C goal achievement in a subgroup of patients

From Lankisch.1
OPAL=Orals Plus Apidra® and Lantus®.
Main meal=meal producing the highest elevation of BG.

Results from a 26-week, multicenter, randomized, open-label, parallel-group study of 316 patients with type 2 diabetes who were suboptimally controlled with Lantus® + OADs. Patients were randomized to the breakfast group (n=162) or the main meal group (n=154). One dose of Apidra® was added to their existing therapy to assess the relative efficacy of administering prandial insulin before breakfast or before the main meal.

Effect on weight

Rates of AEs in the OPAL study

Severe hypoglycemia

Adverse Events

Indications and Usage for Lantus® (insulin glargine [rDNA origin] injection)

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Indications and Usage for Apidra® (insulin glulisine [rDNA origin] injection)

Apidra® is a rapid-acting insulin analog indicated to improve glycemic control in adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes.

When used as a mealtime insulin, the dose of Apidra® should be given within 15 minutes before or within 20 minutes after starting a meal. Apidra® given by subcutaneous injection should normally be used in regimens that include a longer-acting insulin.

Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection) & Apidra® (insulin glulisine [rDNA origin] injection)

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Apidra® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Apidra® or any of its excipients.

Warnings and Precautions

Closely monitor blood glucose in all patients treated with insulin. Modify insulin regimens cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. As with all insulin preparations, the time course of action may vary by individual or at different times in the same individual and is dependent on many conditions, including the site of injection, local blood supply, or local temperature.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus® and Apidra®, and may be serious and life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus® and/or Apidra®, monitor and treat if indicated.

A reduction in the Lantus® and/or Apidra® dose may be required in patients with renal or hepatic impairment.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Adverse reactions commonly associated with Lantus® and Apidra® include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Please click here for Full Prescribing Information for Lantus®.

Please click here for Full Prescribing Information for Apidra® .

References:

  1. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA; Orals Plus Apidra and Lantus (OPAL) study group. Diabetes Obes Metab. 2008;10(12): 1178-1185.
  2. Nathan DM, Buse JB, Davidson MB, et al. Diabetes Care. 2009;32(1): 193-203.
  3. Raccah D, Bretzel RG, Owens D, Riddle M. Diabetes Metab Res Rev. 2007;23(4): 257-264.
  4. Data on file, Sanofi U.S. LLC.

Indications and Usage for Lantus® (insulin glargine [rDNA origin] injection)

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection)

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Click here for additional Important Safety Information.

  • Indications and Usage for Lantus®

    (insulin glargine [rDNA origin] injection)

    Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

    Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

    Important Safety Information for Lantus®

    (insulin glargine [rDNA origin] injection)

    Contraindications
    Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

    Warnings and Precautions
    Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

    Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

    Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

    Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus®, monitor and treat if indicated.

    A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

    Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

    Drug Interactions
    Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

    Adverse Reactions
    Adverse reactions commonly associated with Lantus® include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

    Important Safety Information for Lantus® SoloSTAR®

    Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

    Click here for Full Prescribing Information for Lantus®.

    Click here for information on drug anti-counterfeiting.

Bookmark this page
or add it to your home screen
for quick access